Skip to main content

Table 1 Patient characteristics

From: A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors

Characteristic Patients, n (%)
Patients enrolled 16
Age (yrs)
 Median 49
 Range 30–67
Sex
 Male 7 (44)
 Female 9 (56)
ECOG performance status
 0 3 (19)
 1 13 (81)
Tumor type
 Breast cancer 4 (25)
 Pancreatic cancer 5 (31)
 gastric cancer 4 (25)
 Other 3 (19)
Previous treatment
 Surgery 14 (88)
 Radiotherapy 9 (56)
 Chemotherapy 16 (100)
  1. Abbreviation: ECOG Eastern Cooperative Oncology Group